Loading...
XSWXROG
Market cap224bUSD
Dec 20, Last price  
247.40CHF
1D
0.28%
1Q
-8.10%
Jan 2017
6.36%
Name

Roche Holding AG

Chart & Performance

D1W1MN
XSWX:ROG chart
P/E
17.45
P/S
3.42
EPS
14.17
Div Yield, %
3.78%
Shrs. gr., 5y
-1.34%
Rev. gr., 5y
-0.26%
Revenues
60.44b
-4.49%
31,273,000,00035,511,000,00042,041,000,00046,133,000,00045,617,000,00049,051,000,00047,473,000,00042,531,000,00045,499,000,00048,612,000,00049,866,000,00050,403,000,00052,636,000,00055,746,000,00059,497,000,00063,751,000,00058,323,000,00062,801,000,00063,281,000,00060,441,000,000
Net income
11.50b
-7.43%
6,641,000,0006,730,000,0007,880,000,0009,761,000,0008,969,000,0007,784,000,0008,666,000,0009,343,000,0009,539,000,00011,164,000,0009,332,000,0008,863,000,0009,576,000,0008,633,000,00010,500,000,00013,497,000,00014,295,000,00013,930,000,00012,421,000,00011,498,000,000
CFO
16.10b
-10.03%
7,335,000,0009,975,000,00010,329,000,00011,728,000,00012,177,000,00016,877,000,00014,342,000,00012,954,000,00015,005,000,00015,772,000,00015,930,000,00015,251,000,00015,001,000,00018,024,000,00019,979,000,00022,385,000,00018,160,000,00020,569,000,00017,890,000,00016,095,000,000
Dividend
Mar 14, 20249.6 CHF/sh
Earnings
Jan 30, 2025

Profile

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, and internationally. The company offers pharmaceutical products in the therapeutic areas of oncology, neuroscience, infectious diseases, immunology, hemophilia, ophthalmology, dermatology, respiratory, anemia, inflammatory and autoimmune, and transplantation. It also offers in vitro tests for the diagnosis of various diseases, such as cancer, cardiovascular, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases. In addition, the company supplies diagnostic instruments and reagents. It has a research collaboration agreement with Synlogic, Inc. for the discovery of a novel synthetic biotic for the treatment of inflammatory bowel disease (IBD). Roche Holding AG was founded in 1896 and is headquartered in Basel, Switzerland.
URL
https://www.roche.com/
IPO date
May 04, 2001
Employees
103,613
Domiciled in
CH
Incorporated in
CH

Valuation

Title
CHF in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
60,441,000
-4.49%
63,281,000
0.76%
62,801,000
7.68%
Cost of revenue
45,438,000
56,727,000
45,316,000
Unusual Expense (Income)
NOPBT
15,003,000
6,554,000
17,485,000
NOPBT Margin
24.82%
10.36%
27.84%
Operating Taxes
1,721,000
2,796,000
2,463,000
Tax Rate
11.47%
42.66%
14.09%
NOPAT
13,282,000
3,758,000
15,022,000
Net income
11,498,000
-7.43%
12,421,000
-10.83%
13,930,000
-2.55%
Dividends
(7,590,000)
(7,446,000)
(7,773,000)
Dividend yield
3.86%
3.20%
2.38%
Proceeds from repurchase of equity
(1,144,000)
(2,514,000)
(20,397,000)
BB yield
0.58%
1.08%
6.26%
Debt
Debt current
4,691,000
4,262,000
15,451,000
Long-term debt
27,664,000
22,282,000
17,101,000
Deferred revenue
227,000
254,000
246,000
Other long-term liabilities
5,470,000
6,607,000
8,606,000
Net debt
20,942,000
15,680,000
18,318,000
Cash flow
Cash from operating activities
16,095,000
17,890,000
20,569,000
CAPEX
(3,742,000)
(4,552,000)
(4,549,000)
Cash from investing activities
(10,643,000)
(3,568,000)
(6,550,000)
Cash from financing activities
(4,239,000)
(15,718,000)
(12,703,000)
FCF
10,563,000
2,890,000
13,880,000
Balance
Cash
10,510,000
9,767,000
13,031,000
Long term investments
903,000
1,097,000
1,203,000
Excess cash
8,390,950
7,699,950
11,093,950
Stockholders' equity
46,402,000
32,015,000
28,345,000
Invested Capital
61,351,050
53,642,050
54,628,050
ROIC
23.10%
6.94%
28.66%
ROCE
21.33%
10.57%
26.35%
EV
Common stock shares outstanding
804,000
800,000
860,000
Price
244.50
-15.83%
290.50
-23.37%
379.10
22.69%
Market cap
196,578,000
-15.41%
232,400,000
-28.72%
326,026,005
21.98%
EV
234,607,000
252,103,000
348,200,005
EBITDA
18,477,000
10,378,000
21,932,000
EV/EBITDA
12.70
24.29
15.88
Interest
997,000
608,000
341,000
Interest/NOPBT
6.65%
9.28%
1.95%